Evidence map›Paper›PMID 34513715›Full record

ArticleFrontiers in oncology2021

Consistent B Cell Receptor Immunoglobulin Features Between Siblings in Familial Chronic Lymphocytic Leukemia.

P Martijn Kolijn, Alice F Muggen, Viktor Ljungström, Andreas Agathangelidis, Ingrid L M Wolvers-Tettero, H Berna Beverloo, Karol Pál, Paul J Hengeveld, Nikos Darzentas, Rudi W Hendriks and 3 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 7 institutions in 5 countries.

P Martijn KolijnLaboratory Medical Immunology, Department of Immunology, Erasmus MC, University Medical Center, Rotterdam, Netherlands.
Alice F MuggenLaboratory Medical Immunology, Department of Immunology, Erasmus MC, University Medical Center, Rotterdam, Netherlands.
Viktor LjungströmDepartment of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
Andreas AgathangelidisInstitute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece.
Ingrid L M Wolvers-TetteroLaboratory Medical Immunology, Department of Immunology, Erasmus MC, University Medical Center, Rotterdam, Netherlands.
H Berna BeverlooDepartment of Clinical Genetics, Erasmus MC, University Medical Center, Rotterdam, Netherlands.
Karol PálCEITEC - Central European Institute of Technology, Masaryk University, Brno, Czechia.
Paul J HengeveldLaboratory Medical Immunology, Department of Immunology, Erasmus MC, University Medical Center, Rotterdam, Netherlands.
Nikos DarzentasDepartment of Hematology, University Hospital Schleswig-Holstein, Kiel, Germany.
Rudi W HendriksDepartment of Pulmonary Medicine, Erasmus MC, University Medical Center, Rotterdam, Netherlands.
Jacques J M van DongenDepartment of Immunology, LUMC, Leiden, Netherlands.
Richard RosenquistDepartment of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
Anton W LangerakLaboratory Medical Immunology, Department of Immunology, Erasmus MC, University Medical Center, Rotterdam, Netherlands.
Erasmus MC · NLCentral European Institute of Technology – Masaryk University · CZCentre for Research and Technology Hellas · GRKarolinska University Hospital · SELeiden University Medical Center · NLUniversity Hospital Schleswig-Holstein · DEUppsala University · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Key processes in the onset and evolution of chronic lymphocytic leukemia (CLL) are thought to include chronic (antigenic) activation of mature B cells through the B cell receptor (BcR), signals from the microenvironment, and acquisition of genetic alterations. Here we describe three families in which two or more siblings were affected by CLL. We investigated whether there are immunogenetic similarities in the leukemia-specific immunoglobulin heavy (IGH) and light (IGL/IGK) chain gene rearrangements of the siblings in each family. Furthermore, we performed array analysis to study if similarities in CLL-associated chromosomal aberrations are present within each family and screened for somatic mutations using paired tumor/normal whole-genome sequencing (WGS). In two families a consistent IGHV gene mutational status (one IGHV-unmutated, one IGHV-mutated) was observed. Intriguingly, the third family with four affected siblings was characterized by usage of the lambda IGLV3-21 gene, with the hallmark R110 mutation of the recently described clinically aggressive IGLV3-21

Indexed as

BCR stereotypyCLL (Chronic Lymphocytic Leukemia)CLL developmentFamilial CLLIGLV3-21 R110

Identifiers

PMID34513715
PMCPMC8427434
OpenAlexW3198620937

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.